Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(13):1108-1110; doi:10.1093/jnci/91.13.1108
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Miller, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 13, 1108-1110, July 7, 1999
© 1999 Oxford University Press

NEWS

PSA as a Treatment Marker for Prostate Cancer?

Mike Miller

Since the use of prostate specific antigen testing for prostate cancer exploded in the late 1980s, PSA has made the diagnosis and treatment of the disease more complex. In the past few years, the PSA test has played an even more pervasive role as a treatment marker, even though its benefits as a detection tool still await the outcome of several randomized clinical trials.

Indeed, of the 54 abstracts presented at the recent American Society of Clinical Oncology meeting that dealt with prostate cancer, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?